DexCom, Inc.

DexCom, Inc. is an American multinational healthcare company specializing in the development, manufacturing, and distribution of continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999, the company's mission is to empower individuals to take control of their health through innovative glucose biosensing technology. DexCom's global headquarters are located in San Diego, California, U.S..

The company's product portfolio includes key CGM systems such as the Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. These systems provide real-time glucose data and trend information, serving both Type 1 and Type 2 diabetes patients, including those who do not use insulin. DexCom also offers digital health solutions like Dexcom Clarity for data analysis and comprehensive support services for users.

DexCom maintains a strong market position as a leader in diabetes care technology, with a significant share in the U.S. CGM market. Recent strategic initiatives include the launch of the Dexcom G7 15-Day Continuous Glucose Monitoring System and the Stelo biosensor, which aims to expand market reach to adults with prediabetes and Type 2 diabetes not on insulin. Under the leadership of CEO Jacob (Jake) Leach, who assumed the role on January 1, 2026, DexCom is pursuing aggressive global expansion and exploring broader biosensing capabilities beyond its current diabetes focus. The company reported robust financial performance with approximately $4.66 billion in revenues for FY25 and projected FY26 revenues of $5.25 billion.